Axa
IMCR icon

Axa’s Immunocore IMCR Stock Holding History

Axa’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-94,919
Closed -$2.98M – 557
2025
Q2 		$2.98M Buy
94,919
+157
+0.2% +$4.88K 0.01% 680
2025
Q1 		$2.81M Sell
94,762
-124
-0.1% -$3.72K 0.01% 670
2024
Q4 		$2.8M Sell
94,886
-154
-0.2% -$4.87K 0.01% 691
2024
Q3 		$2.96M Buy
95,040
+28
+0% +$1.02K 0.01% 669
2024
Q2 		$3.22M Buy
95,012
+55
+0.1% +$2.81K 0.01% 648
2024
Q1 		$6.17M Buy
94,957
+28
+0% +$1.92K 0.02% 510
2023
Q4 		$6.49M Sell
94,929
-2,298
-2% -$119K 0.02% 489
2023
Q3 		$5.05M Buy
+97,227
New +$5.75M 0.02% 525

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Axa's IMCR Position: Q3 2025 in Review

Axa sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 94,919 shares — an estimated $2.98M sold.

Axa first reported a position in IMCR in Q3 2023 and held it in 8 quarters. The position peaked at $6.49M in Q4 2023. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

  • Axa reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
  • Axa sold 94,919 Immunocore shares in Q3 2025, an estimated $2.98M.
  • Axa first reported a position in Immunocore in Q3 2023 and held it in 8 quarters.
  • Axa's Immunocore position peaked at $6.49M in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.